Clinical trials located in

Blagoevgrad

Blagoevgrad city is located in Bulgaria. Currently, 14 clinical trials are being conducted in this city.

Blagoevgrad, nestled in the picturesque foothills of the Pirin Mountains in Bulgaria, boasts a rich history dating back to ancient times. This vibrant city is home to the American University in Bulgaria, a testament to its educational significance. Blagoevgrad’s charming Varosha quarter, with its preserved National Revival architecture, offers a glimpse into the past. The city is also known for its lively cultural scene, hosting the annual Blagoevgrad International Folklore Festival. Surrounded by natural beauty, including the nearby thermal springs, Blagoevgrad serves as a hub for both historical exploration and outdoor activities.

  • CT-EU-00041455

    Study of the effectiveness of tanimilast in the treatment of pulmonary diseases

    A 52-week clinical trial is being conducted to investigate the effectiveness and safety of the new drug, known as Tanimilast (CHF6001), in people diagnosed with chronic bronchitis and chronic obstructive pulmonary disease (COPD). The primary aim of the study is to determine the effectiveness of CHF6001 administered as an addition to a standard COPD treatment regimen. Study participants will be randomly assigned to receive the study drug CHF6001 or a placebo, which will be taken concurrently with their existing COPD therapy. Key measurements in the study include monitoring the frequency and severity of COPD exacerbations, which are episodes of significantly worsening symptoms. Additionally, the study will assess changes in participants’ lung function and overall quality of life. Typically eligible for the study are adults who are 40 years of age or older, have a documented history of COPD and chronic bronchitis, and are current or former smokers. In particular, the study is of interest to people who have experienced at least one COPD exacerbation in the year preceding the study.

    AustriaBulgariaCzechiaGermanyGreeceHungaryNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Testing oral ozanimod for active Crohn’s Disease treatment

    This trial is for a medicine called Ozanimod, that’s taken by mouth. It’s a Phase 3 trial, meaning it’s been tested in smaller trials before and looks promising. The disease we’re looking at is Crohn’s Disease, which can be quite severe. The goal of this trial is to see if Ozanimod can help get the disease under control, this is called an ‘induction therapy’. To make sure the results are accurate, some people will get the real medication while others will get a ‘placebo’, which looks the same but doesn’t have any medicine in it. Everything is double-checked to make sure it’s fair and unbiased.

    BulgariaCzechiaFranceItalyPolandUnited Kingdom
  • Continued study of ozanimod for severe Crohn’s Disease

    This research is about an extended study on the use of an oral medication named Ozanimod for people suffering from Crohn’s disease. Crohn’s disease can make the stomach and intestines really uncomfortable, causing swellings and pain. The main aim of this study is to check if this medicine, Ozanimod, is safe for intake and how effective it is in easing these uncomfortable feelings in the stomach. The researchers will rate patients’ illnesses using the Crohn’s Disease Activity Index (a measurement tool).

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Studying ozanimod as ongoing treatment for Severe Crohn’s Disease

    This trial is to test a medication called Ozanimod on people who have a serious type of Crohn’s Disease. Crohn’s Disease can make the stomach hurt a lot and sometimes makes difficulty eating.  The researchers want to see if the medication helps to calm the disease, so patients feel better. Some patients will get the Ozanimod and others will get a placebo.  The researchers use  ‘Crohn’s Disease Activity Index’ to see how the disease is doing.

    BelgiumBulgariaCzechiaFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Study on risk reduction of heart complications with Milvexian

    This study involves a drug called milvexian, which is being tested for people who have recently experienced a heart-related episode, like a heart attack or stroke (acute coronary syndrome). Half of the participants will receive milvexian, and the other half will get a placebo. The study’s main aim is to show that milvexian can help reduce the chance of major heart-related problems happening again. These problems include things like heart failure, another heart attack, or an ischemic stroke.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom
  • Testing Milvexian’s effectiveness in preventing repeat strokes

    This research trial, called LIBREXIA-STROKE, will test a medication called Milvexian on those who have recently had a stroke or a high-risk ‘mini-stroke’. In its 3rd testing phase, the study will involve a system where the patients won’t know whether they are receiving the actual drug or a substitute with no effect, referred to as a ‘placebo’, to maintain fairness. Milvexian is a medication that can potentially reduce the risk of having another stroke, and this trial aims to observe how effective it is in doing so. The trial will look at when the first stroke happens after starting the trial, if other major heart or limb diseases occur, or if strokes occur in the first 90 days.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    AustriaCzechiaFranceItalyRomaniaSpainUnited Kingdom
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    AustriaBelgiumFrancePolandUnited Kingdom
  • Assessing olpasiran treatment for heart disease and elevated cholesterol

    Tests named ‘OCEAN(a)’ are being conducted, focusing on a medication called ‘olpasiran’. Put simply, the potential of this medication in preventing serious heart episodes in individuals with Atherosclerotic Cardiovascular Disease and an elevated level of a fat protein, Lipoprotein(a), is under examination. The effect of a harmless, dummy pill (placebo) is compared to that of the actual medication, olpasiran, in individuals with these conditions. The primary goal is to determine whether olpasiran can reduce the risk of death due to heart disease, occurrence of heart attacks, or the necessity for sudden surgery to clear blocked heart vessels.

    AustriaBelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalRomaniaSlovakiaSpainSwedenUnited Kingdom
  • Testing astegolimab’s effectiveness in chronic obstructive pulmonary disease patients

    A clinical research study is being conducted to examine the efficacy and safety of a novel treatment known as astegolimab in the management of Chronic Obstructive Pulmonary Disease (COPD). The study is particularly focused on individuals with a history of COPD who are either current or former smokers and have experienced frequent exacerbations. Within the scope of this study, astegolimab’s therapeutic potential is being compared to that of a placebo. Participants enrolled in the trial will be administered the study medication at intervals of either every 2 or 4 weeks. Key parameters under evaluation include the frequency of COPD exacerbations, variations in the quality of life of the participants, and changes in lung function over the course of the study. The study aims to contribute valuable data to medical research, particularly in understanding the treatment dynamics of astegolimab in COPD management.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainSwedenUnited Kingdom
  • Testing the effect and safety of tanimilast for COPD patients

    This study is a year-long experiment where the researchers will test the effectiveness and safety of two doses of a new drug called tanimilast. Tanimilast is added to the usual treatment for people with two lung conditions: COPD and Chronic Bronchitis. The drug will be tested and compared with a group that will take a placebo, a substance with no effect. The main aim is to see if tanimilast helps control the worsening of symptoms in COPD patients. These worsening instances are known as ‘exacerbations’ and can range in severity. Some might require extra medication.

    AlbaniaAustriaBulgariaCzechiaGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSlovakiaSpainUnited Kingdom
  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    BelgiumDenmarkFinlandFranceGermanyNetherlandsNorwayPortugalSwedenUnited Kingdom
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    AustriaBelgiumFranceGermanyItalySpain
  • Comparison of milvexian and apixaban in reducing stroke risk in patients with atrial fibrillation

    This study is designed to compare two drugs, Milvexian and Apixaban to reduce the potential risk of stroke for patients suffering from atrial fibrillation, a common heart rhythm disorder. 15500 participants, aged 18 years and older will be invited to partake in this research. Participants will be randomly designated to receive either Milvexian or Apixaban. The study team aims to determine if Milvexian is at least as effective as Apixaban in reducing the risk of combined stroke and Non-central nervous system (CNS) systemic embolism. Furthermore, the research team will evaluate the occurrence rates of various health incidents including major bleeding, various cardiovascular complications, death, and other severe conditions over a 4-year period. The goal is to find out which medication proves safer and more effective in preventing severe health risks linked with this disorder. Study commencement is April 11, 2023, with completion targeted at May 5, 2027.

    BelgiumBulgariaCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalRomaniaSlovakiaSpainUnited Kingdom

See more clinical trials in other cities in Bulgaria:

.